Literature DB >> 12732750

Analysis of localized erythema using clinical indicators and spectroscopy.

Stephen Sprigle1, Maureen Linden, Brian Riordan.   

Abstract

Localized erythema is regularly used as an indicator of post-ischemic events, including reactive hyperemia and Stage I pressure ulcers. The National Pressure Ulcer Advisory Panel definition of a Stage I ulcer includes both visual and nonvisual indicators in part to improve identification in darkly pigmented skin. A prospective, repeated-measures design was used to collect information on pressure-induced erythema that includes reactive hyperemia and Stage I pressure ulcers with an emphasis on distinguishing indicators in light and dark skin The relationships among clinical indicators (skin assessments) and results from tissue reflectance spectroscopy, as well as the clinical utility of spectroscopy for discerning tissue blanching status, were examined in a convenience sample of 76 inpatients and outpatients (95 test/control site pairs). Chi-square analysis and generalized logistic models were used to identify relationships and distinguishing characteristics of erythema. Analysis of variance was used to analyze blanching using spectroscopy. Nonblanching sites were more likely to be persistent erythema (c2=5.3; P = 0.021) but exhibited no relationships to temperature, tissue resilience, or disability. Erythema in subjects with dark skin was more likely to be nonblanching and have poor resilience. Spectrographic analysis of blanching found significant differences across skin pigmentation (P = 0.0001) and blanching status (P = 0.019). These results reinforce the belief that dark skin must be assessed differently than light skin and indicate that clinicians should use persistence of erythema rather than blanching status to judge incipient pressure ulcers. These results validate the use of visual and nonvisual indicators included in the National Pressure Ulcer Advisory Panel Stage I pressure ulcer definition.

Entities:  

Mesh:

Year:  2003        PMID: 12732750

Source DB:  PubMed          Journal:  Ostomy Wound Manage        ISSN: 0889-5899            Impact factor:   2.629


  7 in total

1.  Improving wound score classification with limited remission spectra.

Authors:  Jana Schmidt; Andreas Hapfelmeier; Wolf-Dieter Schmidt; Uwe Wollina
Journal:  Int Wound J       Date:  2011-11-15       Impact factor: 3.315

2.  Use of prophylactic silicone adhesive dressings for maintaining skin integrity in intensive care unit patients: A randomised controlled trial.

Authors:  Yun J Lee; Jung Y Kim; Woo Y Shin
Journal:  Int Wound J       Date:  2019-03       Impact factor: 3.315

3.  Prognosis of stage I pressure ulcers and related factors.

Authors:  Miwa Sato; Hiromi Sanada; Chizuko Konya; Junko Sugama; Gojiro Nakagami
Journal:  Int Wound J       Date:  2006-12       Impact factor: 3.315

4.  Objective evaluation by reflectance spectrophotometry can be of clinical value for the verification of blanching/non blanching erythema in the sacral area.

Authors:  Eila Sterner; Bjöörn Fossum; Elisabeth Berg; Christina Lindholm; André Stark
Journal:  Int Wound J       Date:  2013-03-24       Impact factor: 3.315

5.  Subepidermal moisture predicts erythema and stage 1 pressure ulcers in nursing home residents: a pilot study.

Authors:  Barbara M Bates-Jensen; Heather E McCreath; Ayumi Kono; Neil Christopher R Apeles; Cathy Alessi
Journal:  J Am Geriatr Soc       Date:  2007-08       Impact factor: 5.562

6.  Predicting the different progressions of early pressure injury by ultraviolet photography in rat models.

Authors:  Huiwen Xu; Yanwei Wang; En Takashi; Akio Kamijo; Daiji Miura; Kunie Karasawa; Akio Kitayama; Jian Lu; Lan Zhang
Journal:  Int Wound J       Date:  2021-09-01       Impact factor: 3.315

Review 7.  Subepidermal moisture (SEM) and bioimpedance: a literature review of a novel method for early detection of pressure-induced tissue damage (pressure ulcers).

Authors:  Zena Moore; Declan Patton; Shannon L Rhodes; Tom O'Connor
Journal:  Int Wound J       Date:  2016-04-29       Impact factor: 3.315

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.